Werewolf Therapeutics, Inc.
HOWLWerewolf Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer and immune-mediated conditions.
Earnings
Next report
Nov 3, 2026 (in 3 months)Competitors
By market cap
By revenue growth
Profile
Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer and immune-mediated conditions. The company utilizes its proprietary PREDATOR platform to engineer conditionally activated molecules, known as INDUKINE and INDUCER candidates, designed to stimulate the immune system selectively within the tumor microenvironment while minimizing systemic toxicity. Currently, the company is undergoing a strategic restructuring to explore alternatives including potential sales, mergers, or licensing arrangements to advance its pipeline.
An innovative developer of tumor-selective immunotherapies currently undergoing a strategic review and restructuring to maximize stockholder value.
FAQ
- What is Werewolf Therapeutics, Inc.'s market cap?
- Werewolf Therapeutics, Inc. (HOWL) has a market capitalization of $18.6M and trades on NASDAQ.
- Who are Werewolf Therapeutics, Inc.'s competitors?
- Werewolf Therapeutics, Inc.'s key competitors include Xilio Therapeutics, Amgen Inc., Bristol-Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Werewolf Therapeutics, Inc. partner with?
- Werewolf Therapeutics, Inc.'s notable partners include Merck & Co., Inc., Jazz Pharmaceuticals Ireland Limited, Piper Sandler & Co.
- Where is Werewolf Therapeutics, Inc. headquartered?
- Werewolf Therapeutics, Inc. is headquartered in United States of America and employs approximately 46 people. It has been publicly traded since 2021.